ArticleIJID regions2026
Serologic evidence of mpox virus exposure among people living with human immunodeficiency virus in Thailand predating clinical recognition during the 2022 outbreak.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Mpox (also known as Methods: Archived 2022 specimens from an acute human immunodeficiency virus cohort were selected based on risk criteria, including multiple partners, a history of sexually transmitted infection, or drug use. Samples were tested using the Meso Scale Discovery V-PLEX Orthopoxvirus immunoglobulin G assay (Meso Scale Discovery, Rockville, MD, USA). Demographic, clinical, and behavioral data were analyzed using Mann-Whitney Results: Of 491 participants, 5.5% (27/491) were seropositive. Seropositivity was detected as early as January 2022, predating Thailand's first clinical case (July 2022) and wastewater detection (June 2022). Only 7.4% (2/27) of seropositive participants had abnormal physical examinations. Illicit drug use (74.1%) and meeting multiple behavioral risk criteria were significantly associated with seropositivity ( Conclusion: Unrecognized, paucisymptomatic mpox transmission occurred in Thailand months before official detection. These findings highlight the utility of serologic surveillance within established high-risk cohorts for the early detection of emerging infectious threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.